首页> 外文期刊>Diabetes >Inhibition of Ca~(2+)-Independent Phospholipase A_2β (iPLA_2β) Ameliorates Islet Infiltration and Incidence of Diabetes in NOD Mice
【24h】

Inhibition of Ca~(2+)-Independent Phospholipase A_2β (iPLA_2β) Ameliorates Islet Infiltration and Incidence of Diabetes in NOD Mice

机译:抑制Ca〜(2+)依赖性磷脂酶A_2β(iPLA_2β)可改善NOD小鼠的胰岛浸润和糖尿病的发生。

获取原文
获取原文并翻译 | 示例
           

摘要

Autoimmune β-cell death leads to type 1 diabetes, and with findings that Ca~(2+)-independent phospholipase A_2β (iPLA_2 β) activation contributes to p-cell death, we assessed the effects of iPLA_2β inhibition on diabetes development. Administration of FKGK18, a reversible iPLA_2β inhibitor, to NOD female mice significantly reduced diabetes incidence in association with 1) reduced insulitis, reflected by reductions in CD4~+ T cells and B cells; 2) improved glucose homeostasis; 3) higher circulating insulin; and 4) β-cell preservation. Furthermore, FKGK18 inhibited production of tumor necrosis factor-α (TNF-α) from CD4~+ T cells and antibodies from B cells, suggesting modulation of immune cell responses by iPLA_2β-derived products. Consistent with this, 1) adoptive transfer of diabetes by CD4~+ T cells to immunodeficient and diabetes-resistant NOD.scid mice was mitigated by FKGK18 pretreatment and 2) TNF-α production from CD4~+ T cells was reduced by inhibitors of cyclooxygenase and 12-lipoxygenase, which metabolize arachidonic acid to generate bioactive inflammatory eicosanoids. However, adoptive transfer of diabetes was not prevented when mice were administered FKGK18-pretreated T cells or when FKGK18 administration was initiated with T-cell transfer. The present observations suggest that iPLA_2β-derived lipid signals modulate immune cell responses, raising the possibility that early inhibition of iPLA_2β may be beneficial in ameliorating autoimmune destruction of β-cells and mitigating type 1 diabetes development.
机译:自身免疫性β细胞死亡导致1型糖尿病,并且发现Ca〜(2+)依赖性磷脂酶A_2β(iPLA_2β)活化可导致p细胞死亡,我们评估了iPLA_2β抑制作用对糖尿病发展的影响。向NOD雌性小鼠施用可逆性iPLA_2β抑制剂FKGK18,可显着降低糖尿病的发生率,并与1)降低的胰岛炎有关,这反映在CD4〜+ T细胞和B细胞的减少上; 2)改善葡萄糖体内稳态; 3)较高的循环胰岛素; 4)β细胞保存。此外,FKGK18抑制了CD4〜+ T细胞和B细胞抗体产生的肿瘤坏死因子-α(TNF-α),提示iPLA_2β衍生产物对免疫细胞应答的调节。与此相符,1)通过FKGK18预处理减轻了CD4〜+ T细胞将糖尿病过继转移至免疫缺陷和抗糖尿病NOD.scid小鼠的风险; 2)环氧合酶抑制剂减少了CD4〜+ T细胞产生的TNF-α。和12-脂氧合酶,其代谢花生四烯酸以产生具有生物活性的炎性类花生酸。但是,当给小鼠施用FKGK18预处理的T细胞或通过T细胞转移开始FKGK18施用时,不能防止糖尿病的过继转移。目前的观察结果表明,iPLA_2β衍生的脂质信号调节免疫细胞反应,增加了iPLA_2β的早期抑制可能有助于改善β细胞的自身免疫破坏和减轻1型糖尿病发展的可能性。

著录项

  • 来源
    《Diabetes》 |2015年第2期|541-554|共14页
  • 作者单位

    Department of Pathology, University of Alabama at Birmingham, Birmingham, AL,Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL;

    Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL,Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL;

    Laboratory of Organic Chemistry, Department of Chemistry, University of Athens, Athens, Greece;

    Laboratory of Organic Chemistry, Department of Chemistry, University of Athens, Athens, Greece;

    Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL,Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL;

    Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL,Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL;

    Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL,Department of Microbiology, University of Alabama at Birmingham, Birmingham, AL;

    Laboratory of Organic Chemistry, Department of Chemistry, University of Athens, Athens, Greece;

    Comprehensive Diabetes Center, University of Alabama at Birmingham, Birmingham, AL,Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL;

  • 收录信息 美国《科学引文索引》(SCI);美国《化学文摘》(CA);
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号